TY - JOUR
T1 - The neuroendocrine sequelae of paediatric craniopharyngioma
T2 - a 40 year meta-data analysis of 185 cases from three UK centres
AU - Tan, Timothy Shao Ern
AU - Patel, Leena
AU - Gopal-Kothandapani, Jaya Sujatha
AU - Ehtisham, Sarah
AU - Ikazoboh, Esieza Clare
AU - Hayward, Richard
AU - Aquilina, Kristian
AU - Skae, Mars
AU - Thorp, Nicky
AU - Pizer, Barry
AU - Didi, Mohammed
AU - Mallucci, Conor
AU - Blair, Joanne C
AU - Gaze, Mark N
AU - Kamaly-Asl, Ian
AU - Spoudeas, Helen
AU - Clayton, Peter E
PY - 2017
Y1 - 2017
N2 - Objectives The management of paediatric craniopharyngiomas was traditionally complete resection (CR), with better reported tumour control compared to partial resection (PR) or limited surgery (LS). The subsequent shift towards hypothalamic-sparing, conservative surgery with adjuvant radiotherapy (RT) to any residual tumour, aimed at reducing neuroendocrine morbidity, has not been systematically studied. Hence, we reviewed the sequelae of differing management strategies in paediatric craniopharyngioma across three UK tertiary centres over four decades. Methods Meta-data was retrospectively reviewed over two time periods before [1973-2000 (Group A: n=100)] and after [1998-2011 (Group B: n=85)] the introduction of the conservative strategy at each centre. Results Patients either had CR (A-34%, B-19%), PR (A-48%, B-46%) or LS (A-16%, B-34%), with trends reflecting the change in surgical approach over time. Overall recurrence rates between the two periods did not change (A-38% vs. B-32%). More patients received RT in B than A, but recurrence rates were similar: for A, 28% patients received RT with 9 recurrences (32%); for B, 62% received RT with 14 recurrences (26%). However rates of diabetes insipidus (p=0.04), gonadotrophin deficiency (p<0.001) and panhypopituitarism (p=0.001) were lower in B than A. In contrast, post-operative obesity (BMI SDS>+2.0) (p=0.4), hypothalamic (p=0.1) and visual (p=0.3) morbidity rates were unchanged. Conclusion The shift towards more conservative surgery has reduced the prevalence of hormone deficiencies, including diabetes insipidus, which can be life threatening. However, it has not been associated with reduced hypothalamic and visual morbidities, which remain a significant challenge. More effective targeted therapies are necessary to improve outcomes.
AB - Objectives The management of paediatric craniopharyngiomas was traditionally complete resection (CR), with better reported tumour control compared to partial resection (PR) or limited surgery (LS). The subsequent shift towards hypothalamic-sparing, conservative surgery with adjuvant radiotherapy (RT) to any residual tumour, aimed at reducing neuroendocrine morbidity, has not been systematically studied. Hence, we reviewed the sequelae of differing management strategies in paediatric craniopharyngioma across three UK tertiary centres over four decades. Methods Meta-data was retrospectively reviewed over two time periods before [1973-2000 (Group A: n=100)] and after [1998-2011 (Group B: n=85)] the introduction of the conservative strategy at each centre. Results Patients either had CR (A-34%, B-19%), PR (A-48%, B-46%) or LS (A-16%, B-34%), with trends reflecting the change in surgical approach over time. Overall recurrence rates between the two periods did not change (A-38% vs. B-32%). More patients received RT in B than A, but recurrence rates were similar: for A, 28% patients received RT with 9 recurrences (32%); for B, 62% received RT with 14 recurrences (26%). However rates of diabetes insipidus (p=0.04), gonadotrophin deficiency (p<0.001) and panhypopituitarism (p=0.001) were lower in B than A. In contrast, post-operative obesity (BMI SDS>+2.0) (p=0.4), hypothalamic (p=0.1) and visual (p=0.3) morbidity rates were unchanged. Conclusion The shift towards more conservative surgery has reduced the prevalence of hormone deficiencies, including diabetes insipidus, which can be life threatening. However, it has not been associated with reduced hypothalamic and visual morbidities, which remain a significant challenge. More effective targeted therapies are necessary to improve outcomes.
U2 - 10.1530/EJE-16-0812
DO - 10.1530/EJE-16-0812
M3 - Article
C2 - 28073908
SN - 0804-4643
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
ER -